165 / 1084
Prognosis and
Treatment decisions
•
PD-L1 expression is rare
•
MSI-subtypes nearly
non-existent
•
EBV-subtypes
non-existent
•
Her2/neu
amplification/overexpressio
n: about 15%
Trastuzumab in Her2-positive
adenocarcinoma
Institute of Pathology | Alexander Quaas
Gastrointestinal Cancer Group Cologne (GCGC)
Checkpoint-inhibition in
ESCC and EAC perhaps less
effective than in lung cancer
•
TP53 wildtype carcinoma:
favourable prognosis?
Determination of TP53 helpful?
1) PD-L1 in esophageal carcinoma – different expression pattern on mRNA and protein level;
L. Tharun......and A. Quaas
2) Epithelial PD-L2 expression marks Barrett's Esophagus and Esophageal Adenocarcinoma;
S. Derks..... and A. Bass
3) The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis;
O. M Fisher.... and
R. V Lord - „p
atients with OAC and TP53 gene mutations have reduced overall survival compared with patients without these
mutations, and this effect is independent of tumour stage“.
4) Radiation sensitivity in a preclinical mouse model of medulloblastoma relies on the function of the intrinsic apoptotic pathway; A.J.
Crowther......and T.R Gershon